These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 6831882)

  • 21. [Severe course of a hemolytic-uremic syndrome].
    Leichter H; Hellwege HH; Altrogge H
    Monatsschr Kinderheilkd; 1982 Nov; 130(11):849-51. PubMed ID: 7155151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Bacillary dysentery and hemolytic-uremic syndrome. Apropos of a case].
    Dalens B; Picon G; Arnal JC; Maurin JL; Unal D
    Pediatrie; 1980; 35(8):707-13. PubMed ID: 7465306
    [No Abstract]   [Full Text] [Related]  

  • 23. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome.
    Yassa SK; Blessios G; Marinides G; Venuto RC
    Clin Transplant; 2005 Jun; 19(3):423-6. PubMed ID: 15877809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of a synthetic hapten in the demonstration of the Thomsen-Friedenreich (T) antigen on neuraminidase-treated human red blood cells and lymphocytes.
    Bray J; Lemieux RU; McPherson TA
    J Immunol; 1981 May; 126(5):1966-9. PubMed ID: 7217675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hemolytic uremic syndrome with hypocomplementemia and deposits of IgM and C3 in the involved renal tissue.
    Gonzalo A; Mampaso F; Gallego N; Bellas C; Segui J; Ortuño J
    Clin Nephrol; 1981 Oct; 16(4):193-9. PubMed ID: 7028337
    [No Abstract]   [Full Text] [Related]  

  • 26. [Specificity of lectins with a broad agglutination spectrum. VII. Further studies with Maclura aurantiaca agglutinin].
    Sprenger I; Uhlenbruck G; Pardoe GI
    Haematologia (Budap); 1970; 4(3):373-8. PubMed ID: 5535563
    [No Abstract]   [Full Text] [Related]  

  • 27. Detection of circulating T-activating enzyme in the serum of a patient having hemolytic-uremic syndrome and disseminated intravascular coagulation.
    Beattie KM; Lewis PE; Briski JE; Strauch BM
    Am J Clin Pathol; 1985 Aug; 84(2):244-8. PubMed ID: 4025230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Catastrophic relapse of Evans syndrome five years after allogeneic BMT notwithstanding full donor chimerism. Terminal hemolytic-uremic syndrome.
    Marmont AM; Gualandi F; Occhini D; Morandi F; Ferretti E; Pezzolo A; Strada P; Ravetti JL; Pistoia V; Falanga A; Bacigalupo A
    Autoimmunity; 2006 Sep; 39(6):505-11. PubMed ID: 17060030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of defective complement control in hemolytic uremic syndrome.
    Zipfel PF; Misselwitz J; Licht C; Skerka C
    Semin Thromb Hemost; 2006 Mar; 32(2):146-54. PubMed ID: 16575689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum immunoglobulin levels in the hemolytic-uremic syndrome in children.
    Monnens L; Samwel-Mantingh M; Lestijo BJ; van Munster P
    Acta Paediatr Belg; 1980; 33(3):157-61. PubMed ID: 7211347
    [No Abstract]   [Full Text] [Related]  

  • 31. Characterization and quantification of anti-T in human serum using a reliable hemolysis test.
    Lynen R; Simson G; Rumpf KW; Neumeyer H
    Vox Sang; 1991; 61(4):258-64. PubMed ID: 1776243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hemolytic uremic syndrome in childhood: study of several factors potentially related with its genesis].
    Olavarría F; Mezzano S; Reinoso S; Delucchi A; Prado V
    Rev Med Chil; 1994 Jan; 122(1):36-41. PubMed ID: 8066341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Verocytotoxigenic Escherichia coli serologic responses in patients with hemolytic uremic syndrome.
    Goldwater PN; Bettelheim KA
    J Infect Dis; 2002 Aug; 186(4):582; author reply 582-3. PubMed ID: 12195391
    [No Abstract]   [Full Text] [Related]  

  • 34. The complement system in hemolytic-uremic syndrome in childhood.
    Monnens L; Molenaar J; Lambert PH; Proesmans W; van Munster P
    Clin Nephrol; 1980 Apr; 13(4):168-71. PubMed ID: 7379368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Where next with atypical hemolytic uremic syndrome?
    Jokiranta TS; Zipfel PF; Fremeaux-Bacchi V; Taylor CM; Goodship TJ; Noris M
    Mol Immunol; 2007 Sep; 44(16):3889-900. PubMed ID: 17768107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hemolytic-uremic syndrome, low C-3 and positive ANCA].
    Castellano I; Pereira LF; Gómez-Martino JR; Covarsí A
    Nefrologia; 2006; 26(1):146-7. PubMed ID: 16649441
    [No Abstract]   [Full Text] [Related]  

  • 37. Association between the epidemic form of hemolytic-uremic syndrome and HLA-B 40 in The Netherlands and Flanders.
    Van de Kar N; Reekers P; van Acker K; Donckerwolcke R; Ploos van Amstel S; Proesmans W; Wolff E; Monnens L
    Nephron; 1991; 59(1):170. PubMed ID: 1944739
    [No Abstract]   [Full Text] [Related]  

  • 38. A simultaneous modification of A agglutinogen of erythrocytes and loss of specific platelet antigens in a patient with gall bladder carcinoma.
    Májský A; Jakoubková J
    Neoplasma; 1969 Jun; 16(3):297-301. PubMed ID: 5349799
    [No Abstract]   [Full Text] [Related]  

  • 39. Anticardiolipin antibodies in D+ hemolytic uremic syndrome.
    te Loo M; van der Velden T; Onland W; van den Heuvel L; Monnens L
    Pediatr Nephrol; 2002 Dec; 17(12):1042-6. PubMed ID: 12478355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Renal biopsy in the hemolytic-uremic syndrome in infancy. A study of three cases (author's transl)].
    Fernández-Sanz J; Galera H; Armas JR; Matilla A; Nogales F
    Med Clin (Barc); 1980 Jan; 74(2):48-51. PubMed ID: 7366264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.